Signup/Login
If you want to receive notifications of upcoming IPOs, you need to simply sign up or sign in with social networks.
Signup/Login
Can you determine which companies are good and which ones - the trash?
Free Pro-version
IPO Filter
Monitor
IPO today
Knowbe4, Inc. (KNBE)
Zymergen Inc. (ZY)
Neuropace Inc (NPCE)
Upcoming IPO
Agiliti, Inc (AGTI)
Treace Medical Concepts, Inc. (TMCI)
Latham Group, Inc. (SWIM)
Rain Therapeutics Inc. (RAIN)
Impel Neuropharma, Inc. (IMPL)
Ftc Solar, Inc. (FTCI)
Aveanna Healthcare Holdings Inc. (AVAH)
Endeavor Group Holdings (EDR)
The Fortegra Group, Inc. (FRF)
Privia Health Group, Inc. (PRVA)
Priced IPO
Uipath Inc (PATH)
Doubleverify Holdings, Inc. (DV)
Skywater Technology, Inc. (SKYT)
Infobird (IFBD)
Troika Media Group, Inc. (TRKA)
Biomea Fusion, Inc. (BMEA)
Akoya Biosciences, Inc. (AKYA)
Recursion Pharmaceuticals, Inc. (RXRX)
Karat Packaging Inc. (KRT)
AppLovin (APP)
Esports Technologies (EBET)
Agilon Health, Inc. (AGL)
TuSimple Holdings Inc (TSP)
Coinbase Global, Inc. (COIN)
Alkami Technology, Inc. (ALKT)
Reneo Pharmaceuticals, Inc. (RPHM)
Vectivbio Holding Ag (VECT)
UTime Limited (UTME)
Frontier Group Holdings (ULCC)
Compass, Inc. (COMP)
More companies

Ikena Oncology, Inc. (IKNA)

Sector - Healthcare

Price chart

+32.93%
Return from IPO

Company News

IPO Profile

About company

They are a targeted oncology company focused on developing novel cancer therapies targeting key signaling pathways that drive the formation and spread of cancer. Their programs focus on key cancer driver pathways that are well-validated in scientific literature but lack approved or effective therapies and therefore have the potential to address high unmet medical needs. By leveraging their deep understanding of discovery chemistry, translational science, and patient-centric drug development, they have built a deep pipeline of wholly owned and partnered programs focused on genetically defined or biomarker-driven cancers, which enables them to target specific patient populations that they believe are most likely to respond to treatment with their product candidates. Since they commenced operations in 2016, they have discovered or developed five oncology programs that include four product candidates in either IND-enabling studies or clinical development. Their lead targeted oncology product candidate, IK-930, is an oral small molecule inhibitor of the transcriptional enhanced associate domain, or TEAD, transcription factor in the Hippo signaling pathway. They intend to submit an Investigational New Drug application, or IND, to the U.S. Food and Drug Administration, or FDA, for IK-930 in the second half of 2021.
Industry
Biological Products (no Diagnostic Substances)
CEO CFO
Mark Manfredi Douglas R. Carlson
Employees Founded
33 2016

Contacts

Address: 645 Summer Street, Suite 101 Boston, Ma 02210

Telephone: (857) 273-8343

Web page: http://www.ikenaoncology.com

IPO information

First Trade Date 3/26/2021
Status Priced
Exchange NASDAQ
Lockup Period Expiration .Pro
Quiet Period Expiration .Pro
Old Price Range
-
Share prices ($)

Shares & Volumes

Shares Initial (MM) 7.8
Shares Revised (MM) 7.8
Expected offer amount (MM) $124.8
Realized offer amount(MM) $117

Financial Data (last reporting year)

Market Cap (MM) $553.44
Revenues (MM) $0
Net Income (Loss) (MM) $-44.3

Voting

What do you think will happen with the IKNA share price after the next 3-6 months? 🔥 (+ 10% or more, flat (+ -10%), -10% or less)

Number of votes: img
The lead left underwriter: Jefferies

IPOs led by the firm .Pro
Profitability of conducted IPOs  ?  .Pro
1st day change  ?  .Pro
Change for the first 3 months  ?  .Pro
Underwriters
Jefferies/ Cowen/ Credit Suisse/ William Blair
CO-Managers
-

Sector: Healthcare

Tweets about $IKNA

Tweets volume:

RT volume:

Timeframe:

Google Trends Stats